Reducing unnecessary premedication prior to parenteral iron therapy: A quality improvement project

Abstract

AbstractBackgroundIntravenous (IV) iron carries risks of mild, self‐limiting, tryptase‐negative Fishbane and complement activation‐related pseudo‐allergy reactions, with rare reports of anaphylaxis. Historically, high‐molecular‐weight iron dextran (HMWID) was associated with a higher incidence of anaphylaxis and empiric premedication with antihistamines/corticosteroids have been used to mitigate this risk. HMWID is no longer available and the risk of hypersensitivity reactions with newer IV iron formulations is low. Therefore, the use of routine prophylactic premedication in all patients is not justified but should be considered in high‐risk patients.Study Design and MethodsOur primary aim was to reduce inappropriate premedication before IV iron administration by 50% so that our institution's hematology providers only prescribe premedications to patients at high risk of having a severe reaction. Interventions included a multidisciplinary education initiative to highlight current evidence against universal administration of premedications and revision of the IV iron informed consent form and electronic order set.ResultsWe measured the success of our intervention by comparing data collected during a 6‐month pre‐intervention period (837 infusions) to a 6‐month post‐intervention period (947 infusions). Inappropriate administration of premedications decreased from 79% in the pre‐intervention period compared to 65% in the post‐intervention period. We found no significant difference in the number of Fishbane reactions, severe reactions, and emergency room admissions, despite this reduction in premedication use.DiscussionAlthough we did not reach our goal of a 50% reduction in inappropriate premedication use, opportunities for process improvements were uncovered and are being explored in the next cycle of this quality improvement project.